Home Cart Sign in  
Chemical Structure| 4425-56-3 Chemical Structure| 4425-56-3

Structure of 4425-56-3

Chemical Structure| 4425-56-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 4425-56-3 ]

CAS No. :4425-56-3
Formula : C5H3N3O2
M.W : 137.10
SMILES Code : N#CC1=CNC(NC1=O)=O
MDL No. :MFCD00051958
InChI Key :HAUXRJCZDHHADG-UHFFFAOYSA-N
Pubchem ID :78145

Safety of [ 4425-56-3 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 4425-56-3 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 3.0
Num. H-bond donors 2.0
Molar Refractivity 32.4
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

89.51 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.12
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-0.93
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-1.07
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-1.71
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.2
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-0.48

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.55
Solubility 38.8 mg/ml ; 0.283 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-0.47
Solubility 46.9 mg/ml ; 0.342 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.52
Solubility 4.11 mg/ml ; 0.03 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.8 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.69

Application In Synthesis of [ 4425-56-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 4425-56-3 ]

[ 4425-56-3 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 4425-56-3 ]
  • [ 23945-44-0 ]
  • 2
  • [ 4425-56-3 ]
  • [ 3177-24-0 ]
YieldReaction ConditionsOperation in experiment
With N,N-diethylaniline; trichlorophosphate; at 25 - 115℃; for 3h; To a mixture of the above uracil (15.41 g, 112.5 mmol) and phosphorus oxychloride (157.4 mL, 1.69 mol) was added N,N-diethylaniline (34.2 mL, 225 mmol), cautiously, at 25 C. The reaction was then heated at 115 C. for 3 h after which the mixture was cooled to 40 C. and concentrated in vacuo to remove excess POCl3. The remaining liquid was poured slowly onto ice-water with rapid stirring and the precipitated product was filtered. The aqueous layer was then extracted with chloroform and the extract was washed with 1 N HCl before concentrating in vacuo. This material was combined with the previously filtered material to afford 2,4-dichloro-pyrimidine-5-carbonitrile (15.36 g, 79%).
 

Historical Records

Categories

Related Functional Groups of
[ 4425-56-3 ]

Amides

Chemical Structure| 65-71-4

A178972 [65-71-4]

5-Methylpyrimidine-2,4(1H,3H)-dione

Similarity: 0.87

Chemical Structure| 4401-71-2

A285040 [4401-71-2]

1,3,5-Trimethylpyrimidine-2,4(1H,3H)-dione

Similarity: 0.81

Chemical Structure| 4212-49-1

A273638 [4212-49-1]

5-Ethylpyrimidine-2,4(1H,3H)-dione

Similarity: 0.79

Chemical Structure| 26305-13-5

A127618 [26305-13-5]

2,4-Dihydroxy-5,6-dimethylpyrimidine

Similarity: 0.78

Chemical Structure| 4869-46-9

A161703 [4869-46-9]

1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbaldehyde

Similarity: 0.78

Nitriles

Chemical Structure| 20577-27-9

A125856 [20577-27-9]

2-Oxo-1,2-dihydropyridine-3-carbonitrile

Similarity: 0.63

Chemical Structure| 4241-27-4

A258686 [4241-27-4]

6-Methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile

Similarity: 0.61

Chemical Structure| 769-28-8

A104579 [769-28-8]

4,6-Dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile

Similarity: 0.57

Chemical Structure| 865758-96-9

A141430 [865758-96-9]

2-((6-Chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile

Similarity: 0.55

Chemical Structure| 621-03-4

A147703 [621-03-4]

2-Cyano-N-phenylacetamide

Similarity: 0.55

Related Parent Nucleus of
[ 4425-56-3 ]

Pyrimidines

Chemical Structure| 65-71-4

A178972 [65-71-4]

5-Methylpyrimidine-2,4(1H,3H)-dione

Similarity: 0.87

Chemical Structure| 4401-71-2

A285040 [4401-71-2]

1,3,5-Trimethylpyrimidine-2,4(1H,3H)-dione

Similarity: 0.81

Chemical Structure| 4212-49-1

A273638 [4212-49-1]

5-Ethylpyrimidine-2,4(1H,3H)-dione

Similarity: 0.79

Chemical Structure| 26305-13-5

A127618 [26305-13-5]

2,4-Dihydroxy-5,6-dimethylpyrimidine

Similarity: 0.78

Chemical Structure| 4869-46-9

A161703 [4869-46-9]

1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbaldehyde

Similarity: 0.78